A Phase II, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of the Combination of Inavolisib Plus Enzalutamide Versus Physician's Choice of ARPI or Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer

Summary

This study will evaluate the efficacy and safety of the combination of inavolisib plus enzalutamide compared with physician's choice of alternative androgen receptor pathway inhibitor (ARPi) or docetaxel in biomarker-selected participants with metastatic castrate-resistant prostate cancer (mCRPC) who have received one prior second-generation ARPi.

Eligibility

Age range

18+ years

Sex

Male

Healthy volunteers

No

Interventions

• Drug
  Inavolisib

  Inavolisib will be administered orally as per the schedule specified in the protocol.

• Drug
  Enzalutamide

  Enzalutamide will be administered orally as per the schedule specified in the protocol.

• Drug
  Abiraterone

  Abiraterone will be administered orally as per the schedule specified in the protocol.

• Drug
  Docetaxel

  Docetaxel will be administered intravenously as per the schedule specified in the protocol.

Locations (20)